Marjolein Pompen
Overview
Explore the profile of Marjolein Pompen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stevanovic J, Pompen M, Le H, Rozenbaum M, Tieleman R, Postma M
PLoS One
. 2014 Aug;
9(8):e103974.
PMID: 25093723
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF). Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however, the risk of bleeding and...
2.
Blommestein H, Issa D, Pompen M, Ten Hoor G, Hogendoorn M, Joosten P, et al.
Eur J Haematol
. 2014 Jan;
92(5):398-406.
PMID: 24400940
Objectives: On the basis of two population-based registries, our study aims to calculate the real-world cost-effectiveness of rituximab maintenance compared with observation in relapsed or refractory follicular lymphoma patients who...
3.
van Haalen H, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M
Clin Drug Investig
. 2013 Nov;
34(2):135-46.
PMID: 24243529
Background And Objective: Many patients with type 2 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control. In such cases, Dutch guidelines recommend unlimited up-titration of insulin, yet in...
4.
Essers B, Seferina S, Tjan-Heijnen V, Severens J, Novak A, Pompen M, et al.
Value Health
. 2010 Jan;
13(4):375-80.
PMID: 20088894
Introduction: Geographic transferability of model-based cost-effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost-effectiveness study of...
5.
Pompen M, Gok M, Novak A, van Wuijtswinkel R, Biesma B, Schramel F, et al.
Lung Cancer
. 2008 Sep;
64(1):110-6.
PMID: 18805601
Introduction: Disease management and costs of treatment of patients with unresectable advanced non-small-cell lung cancer (NSCLC) in The Netherlands are not well known. Methods: A retrospective medical chart review was...
6.
Saller B, Mattsson A, Kann P, Koppeschaar H, Svensson J, Pompen M, et al.
Eur J Endocrinol
. 2006 May;
154(6):843-50.
PMID: 16728544
Objective: This study set out to determine the change in quality of life (QoL) and healthcare utilization during 2 years of growth hormone (GH) replacement therapy in adults with GH...
7.
de Riemer M, Reijneke R, Pompen M, Lutter R, Jansen H, Out T
Immunology
. 2002 Apr;
106(1):11-9.
PMID: 11972627
In patients with allergic asthma, T-cell cytokines are implicated in the regulation of the local inflammation in the airways. The ability of sensitized mast cells to release mediators and cytokines...